---
schema_version: "secwatch.filing_event.v1"
accession: "0001837607-24-000083"
form_type: "8-K"
ticker: "AEON"
cik: "0001837607"
company_name: "AEON Biopharma, Inc."
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T10:08:32.840317+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# AEON Biopharma plans biosimilar development of ABP-450 targeting BOTOX; FDA meeting set for Q3 2024

## Summary
- ABP-450 will be developed as a biosimilar using BOTOX as reference product under 351(k) pathway.
- Biosimilar initial advisory meeting with FDA scheduled for Q3 2024.
- Planned Phase 3 cervical dystonia study of ~400 patients to compare ABP-450 to BOTOX.
- No specific financial results for Q2 2024 were disclosed in the press release.
- Company notes development is subject to securing funding.

## SEC filing metadata
- accession: 0001837607-24-000083
- form_type: 8-K
- ticker: AEON
- cik: 0001837607
- company_name: AEON Biopharma, Inc.
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1837607/000183760724000083/0001837607-24-000083-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1837607/000183760724000083/aeon-20240812x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001837607-24-000083
- JSON: https://secwatch.observer/filing/0001837607-24-000083.json
- Plain text: https://secwatch.observer/filing/0001837607-24-000083.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.